IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of

SASAKI et al.

Serial No. 09/869,185

Filed: June 25, 2001

For:

METHOD OF BREEDING YEAS

Attorney Docket No. 46221

Group Art Unit: 1636

Examiner: B. Loeb

RECEIVED

TRANSMITTAL OF RESPONSE

NOV 2 5 2002

Assistant Commissioner for Patents Washington, D.C. 20231

TECH CENTER 1600/2900

Transmitted herewith is an Response in the above-captioned application. The fee has been calculated as shown below. (Small entity fees indicated in parentheses.)

CLAIMS AS AMENDED							
(1)	(2)	(3)	(4)	(5)	(6)	(7)	
	Claims Remaining After Amendment		Highest Number Previously Paid For	Extra Claims	Rate	Fee	
Total Claims	8	-	20	12	18.00	\$0	
(Small Entity)					(9.00)		
Independent claims	8	-	3	2	84.00	\$84.00	
(Small Entity)					(42.00)		
Multiple Dependent	0	-	0	0	280.00	0	
(Small Entity)					(140.00)		
Extension of Time	One Month		Two Months	Three Months			
Fee	\$110		\$400	\$920		\$920.00	
(Small Entity)	(\$55)		(\$200)	(\$460)		0	
Total						\$1,004.00	

The above fees are believed to be correct. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0687 under the above Attorney Docket Number for which purpose this paper is submitted in duplicate.


Respectfully submitted,

Date: November 21, 2002

Paul E. White, Jr.

Reg. No. 32,011 Tel. No. 202-261-1050 Fax No. 202-887-0336

Manelli Denison & Selter, PLLC 2000 M Street, N.W. Suite 700 Washington, D.C. 20036-3307 202.261.1000



Application No.	Applicant(s)	
09/869,185	ASHIKARI ET AL.	
Examiner	Art Unit	
Bronwen M. Loeb	1636	

TICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING JCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

olicant must file the items indicated below within the time period set in the Office action to which the Notice is attached avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 36(a)).

e nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: The sequences on p. 24, lines 18 and 19 lack SEQ ID Nos. It is unknown if these two sequences are listed uputer readable format and paper listing already submitted. If they are already listed in both the CRF and the papering, amending the specification to recite the appropriate SEQ ID No. is sufficient to satisfy the sequence compliance is. However, if these two sequences are not listed, Applicant must provide the items indicated in the following section.

plicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the cification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

- questions regarding compliance to these requirements, please contact;
- Rules Interpretation, call (703) 308-4216
- CRF Submission Help, call (703) 308-4212

entIn Software Program Support

To Purchase Patentin Software......703-306-2600

EASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY